Publication: Plasma nevirapine levels and 24-week efficacy of a fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) among Thai HIV-infected patients
Issued Date
2007-02-01
Resource Type
ISSN
01252208
01252208
01252208
Other identifier(s)
2-s2.0-33847704121
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of the Medical Association of Thailand. Vol.90, No.2 (2007), 244-250
Suggested Citation
Weerawat Manosuthi, Sasisopin Kiertiburanakul, Achara Chaovavanich, Somnuek Sungkanuparph Plasma nevirapine levels and 24-week efficacy of a fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) among Thai HIV-infected patients. Journal of the Medical Association of Thailand. Vol.90, No.2 (2007), 244-250. Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/25005
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Plasma nevirapine levels and 24-week efficacy of a fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) among Thai HIV-infected patients
Abstract
Background: A fixed-dose combination of stavudine, lamivudine, and nevirapine (GPO-VIR) is the most affordable antiretroviral therapy (ART) regimen in Thailand. The data of nevirapine (NVP) level and efficacy of this fixed-dose combination is limited. Material and Method: Patients who were initiated GPO-VIR in 2004 were enrolled. NVP levels at 12 weeks were determined. Patients were followed for 24 weeks. Results: Fifty-nine patients with a mean age of 36.4 years and 54% male were enrolled. Mean body weight was 54.7 kgs. Median baseline CD4 and HIV-RNA were 29 cells/mm3 and 270,000 (5.4 log 10) copies/mL, respectively. Mean plasma NVP levels at 12 weeks was 6.4 mg/L. By linear regression, female gender (p = 0.042), and higher weight (p = 0.020) were associated with lower NVP levels. At 24 weeks, 78% achieved undetectable HIV-RNA and median CD4 was 156 cells/mm3. Conclusion: NVP levels and 24-week efficacy of GPO-VIR are favorable. According to the affordable cost, GPO-VIR should be an appropriate initial regimen for na□ve HIV-infected patients in resource-limited settings.